Gut Microbiome in Probable Intestinal Tuberculosis and Changes following Anti-Tuberculosis Treatment
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Information on the gut microbiome in patients with intestinal tuberculosis (ITB) and changes therein following anti-tuberculosis treatment (ATT) is lacking. We aimed to elucidate differences in stool microbiome between ITB patients and controls and to evaluate stool microbiome changes after ATT. Materials and Methods: Eleven patients with probable ITB underwent ATT for 6 months, with stool samples collected at 0, 2, and 6 months. We performed next-generation sequencing of 16S rRNA genes in stool bacteria and compared the gut microbiome. Results: Initially, the relative abundance of Verrucomicrobia was higher (5.0% vs. <1%) and that of Proteobacteria was lower (<1% vs. 6.6%) in ITB patients than in controls. Higher numbers of butyrate-producing bacteria (Blautia and Roseburia) were noted in ITB patients. The alpha-diversity of stool microbiome of ITB patients was lower than that in controls (p=0.045). There was a significant difference in beta-diversity between the groups (p=0.001). At 6 months, the proportion of Verrucomicrobia decreased to <1%, while the proportion of Proteobacteria remained at <1%. Conclusion: There were no significant differences in alpha- and beta-diversity in the stool microbiome at 0, 2, and 6 months after ATT. The stool microbiome composition of probable ITB patients was different from that of controls, and 6 months of ATT did not significantly affect it.
Abstract
Purpose: Information on the gut microbiome in patients with intestinal tuberculosis (ITB) and changes therein following anti-tuberculosis treatment (ATT) is lacking. We aimed to elucidate differences in stool microbiome between ITB patients and controls and to evaluate stool microbiome changes after ATT. Materials and Methods: Eleven patients with probable ITB underwent ATT for 6 months, with stool samples collected at 0, 2, and 6 months. We performed next-generation sequencing of 16S rRNA genes in stool bacteria and compared the gut microbiome. Results: Initially, the relative abundance of Verrucomicrobia was higher (5.0% vs. <1%) and that of Proteobacteria was lower (<1% vs. 6.6%) in ITB patients than in controls. Higher numbers of butyrate-producing bacteria (Blautia and Roseburia) were noted in ITB patients. The alpha-diversity of stool microbiome of ITB patients was lower than that in controls (p=0.045). There was a significant difference in beta-diversity between the groups (p=0.001). At 6 months, the proportion of Verrucomicrobia decreased to <1%, while the proportion of Proteobacteria remained at <1%. Conclusion: There were no significant differences in alpha- and beta-diversity in the stool microbiome at 0, 2, and 6 months after ATT. The stool microbiome composition of probable ITB patients was different from that of controls, and 6 months of ATT did not significantly affect it.
참고문헌 (30)
- Naidoo CC, "The microbiome and tuberculosis : state of the art, potential applications, and defining the clinical research agenda", Lancet Respir Med, 7, pp.892~906 (2019)
- Ritika Rampal, "Prospective validation of CD4+CD25+FOXP3+ T-regulatory cells as an immunological marker to differentiate intestinal tuberculosis from Crohn’s disease", Intestinal research, 19(2), pp.232~238 (2021), 대한장연구학회[DOI]
- Namasivayam S, "The microbiome and tuberculosis : early evidence for cross talk", mBio, 9, pp.e01420-18~ (2018)[DOI]
- Eribo OA, "The gut microbiome in tuberculosis susceptibility and treatment response : guilty or not guilty?", Cell Mol Life Sci, 77, pp.1497~1509 (2019)
- Hu Y, "Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs", J Infect, 78, pp.317~322 (2019)
- Maji A, "Gut microbiome contributes to impairment of immunity in pulmonary tuberculosis patients by alteration of butyrate and propionate producers", Environ Microbiol, 20, pp.402~419 (2018)
- Marshall JB, "Tuberculosis of the gastrointestinal tract and peritoneum", Am J Gastroenterol, 88, pp.989~999 (1993)
- Park SH, "Prospective randomized trial of six-month versus nine-month therapy for intestinal tuberculosis", Antimicrob Agents Chemother, 53, pp.4167~4171 (2009)
- Chun J, "The analysis of oral microbial communities of wild-type and toll-like receptor 2-deficient mice using a 454 GS FLX Titanium pyrosequencer", BMC Microbiol, 10, pp.101~ (2010)
- Hur M, "Effect of genetically modified poplars on soil microbial communities during the phytoremediation of waste mine tailings", Appl Environ Microbiol, 77, pp.7611~7619 (2011)
- Kim BS, "Impact of enrofloxacin on the human intestinal microbiota revealed by comparative molecular analysis", Anaerobe, 18, pp.310~320 (2012)
- Segata N, "Metagenomic biomarker discovery and explanation", Genome Biol, 12, pp.R60~ (2011)
- Chang HS, "Isolated terminal ileal ulcerations in asymptomatic individuals : natural course and clinical significance", Gastrointest Endosc, 72, pp.1226~1232 (2010)
- Winglee K, "Aerosol Mycobacterium tuberculosis infection causes rapid loss of diversity in gut microbiota", PLoS One, 9, pp.e97048~ (2014)
- Hu Y, "The gut microbiome signatures discriminate healthy from pulmonary tuberculosis patients", Front Cell Infect Microbiol, 9, pp.90~ (2019)
- Luo M, "Alternation of gut microbiota in patients with pulmonary tuberculosis", Front Physiol, 8, pp.822~ (2017)
- Furusawa Y, "Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells", Nature, 504, pp.446~450 (2013)
- Silva JPB, "Protective mechanisms of butyrate on inflammatory bowel disease", Curr Pharm Des, 24, pp.4154~4166 (2018)
- Lachmandas E, "Diabetes mellitus and increased tuberculosis susceptibility : the role of short-chain fatty acids", J Diabetes Res, 2016, pp.6014631~ (2016)
- Takahashi K, "Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease", Digestion, 93, pp.59~65 (2016)
- Laserna-Mendieta EJ, "Determinants of reduced genetic capacity for butyrate synthesis by the gut microbiome in Crohn’s disease and ulcerative colitis", J Crohns Colitis, 12, pp.204~216 (2018)
- Wang Y, "Characteristics of faecal microbiota in paediatric Crohn’s disease and their dynamic changes during infliximab therapy", J Crohns Colitis, 12, pp.337~346 (2018)
- Fredricks DN, "Vaginal and extra-vaginal bacterial colonization and risk for incident bacterial vaginosis in a population of women who have sex with men", J Infect Dis (2020)[DOI]
- Singh R, "Assessing a diagnosis tool for bacterial vaginosis", Eur J Clin Microbiol Infect Dis, 39, pp.1481~1485 (2020)
- Hong BY, "Microbiome changes during tuberculosis and antituberculous therapy", Clin Microbiol Rev, 29, pp.915~926 (2016)
- Wipperman MF, "Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed", Sci Rep, 7, pp.10767~ (2017)
- Yu Mi Lee, "Incidence and Clinical Outcomes of Clostridium difficile Infection after Treatment with Tuberculosis Medication", Gut and Liver, 10(2), pp.250~254 (2016), 거트앤리버 소화기연관학회협의회
- Wang J, "Long-term effects of multi-drug-resistant tuberculosis treatment on gut microbiota and its health consequences", Front Microbiol, 11, pp.53~ (2020)
- Sharma MP, "Abdominal tuberculosis", Indian J Med Res, 120, pp.305~315 (2004)
- Choi EH, "Gastrointestinal tuberculosis", Microbiol Spectr, 4, pp.4.6.21~ (2016)